News

And continued progress of its alpestria-1 clinical phase 2 study in alport syndrome patient Investment seen as further validation of the corporate nutrition benefit market and its ability to manage workforce health and costs. LISBON, Portugal, Sept. 16, 2025 /PRNewswire/  – Nutrium, an all-in-one corporate nutrition solution that helps millions of patients worldwide create personalized meal plans, track progress, manage chronic diseases,

And continued progress of its alpestria-1 clinical phase 2 study in alport syndrome patient ENYO completes €32 million Series C with new €6 million investment from Vesalius Biocapital IV New funds will support two additional clinical studies and expand preclinical research, including in ADPKD Topline results from its ALPESTRIA-1 Phase 2 trial of Vonafexor in Alport Syndrome confirmed for Q4

Inflammatix Raises $57M in Series E Financing NEW YORK, Sep 12, 2024 — Molecular diagnostics firm Inflammatix said Thursday that it has raised $57 million in a Series E funding round. The round was led by Khosla Ventures and Think.Health with participation from Northpond Ventures, D1 Capital Partners, Iberis Capital, Vesalius BioCapital, OSF Healthcare, and RAW Ventures, among others. The

HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver Regeneration Funds to support Phase Ib clinical trial of HRX-215 in the US and an international multicenter Phase IIa clinical trial in liver regeneration Elias Papatheodorou moves from Chair of the Board to CEO of HepaRegeniX Dr. Linda Greenbaum joins HepaRegeniX as CMO Tuebingen (Germany),

Inheart raises $11M to accelerate development & deployment of novel therapeuthic, predictive, and screening cardiac solutions Funding supports commercial expansion of inHEART’s digital twin of the heart in the US, EU, Asia Pacific, and Middle East markets, as well as the development of new software solutions across the cardiac care continuum May 6, 2024 — Cambridge, MA, and Bordeaux, France